Status:
COMPLETED
Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients
Lead Sponsor:
Damanhour University
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
35-80 years
Phase:
NA
Brief Summary
The aim of this study is to evaluate the effect of vildagliptin on copeptin in comparison to glimepiride, and whether copeptin could be used as a marker for the efficacy of vildagliptin in type 2 diab...
Detailed Description
1. Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy, Damanhour University. 2. All participants agreed to take part in this clinical study and provide informed consent. 3...
Eligibility Criteria
Inclusion
- Inclusion criteria
- • 70 uncontrolled adult patients with Type II-diabetes mellitus
- Exclusion criteria
- Hepatic impairment.
- Active malignancy.
- Planned surgical intervention.
- Any signs of hypersensitivity or contraindication to study drugs developed.
- Addition of any anti-diabetic medications or insulin during follows up.
- Chronic inflammatory disease (i.e. inflammatory bowel disease, lupus, inflammatory arthritis, rheumatoid arthritis) or chronic infection (i.e. chronic diabetic foot infection).
- Pregnancy, lactation or child-bearing potential.
- Cardiac disease.
- Renal impairment.
- History of T1DM, SIAD, or diabetes insipidus.
- Therapy with any diuretic or a medication affecting the RAAS.
Exclusion
Key Trial Info
Start Date :
October 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2024
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06068686
Start Date
October 1 2022
End Date
December 1 2024
Last Update
February 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Damanhour Teaching Hospital, General Organization for Teaching Hospitals and Institutes.
Damanhūr, Elbehairah, Egypt, 31527